CSI Market
Sign In | Register

Pfizer Inc (PFE) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access PFE Annual Cash Flow →
From Pfizer Inc through Jun 29 2025, changes in Jun 28 2026's operating cash flow provide insight into underlying business performance trends.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 28 2026)
6 Months 		(Mar 29 2026) (Dec 31 2025) (Sep 28 2025) (Jun 29 2025)
Operating Activities
Income4,898.00
Depreciation & amortization3,235.00
Amortization of Other Assets0.00
Asset impairment charges0.00
Asset Write Offs AndAsset Impairment Charges5,729.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories46.00
Gains on sales of products0.00
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal0.00
Share-based Compensation521.00
Stock-based compensation0.00
Taxes on exercise of stock options0.00
Discontinued Operation Provision For Loss Gain On Disposal Before Income Tax-
Depreciation Depletion And Amortizationincludingdiscontinuedoperations-
Gainlossassociatedwiththetransferofcertainproductrightstoanequitymethodinvestment-
Tax Cuts And Jobs Act Of2017 Income Tax Expense Benefit-
Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest2,709.00
Income taxes0.00
Losses/ -gains on investments net1,870.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable, Trade0.00
Pension contributions0.00
Other Accrued expenses0.00
Pension And Other Postretirement Benefit Contributions Net Of Pension And Other Postretirement Benefit Expense0.00
Other Working Capital3,548.00
Other Noncash Income (Expense)159.00
Other net19.00
Payments for (Proceeds from) Other Operating Activities-16,570.00
Discontinued operations-5.00
Net Cash flow from Operating Activities3,450.00
Investing Activities
Capital Expenditures-969.00
Sale of Capital Items0.00
Short-term Investments Proceeds1,501.00
Payments to Acquire Marketable Securities-95.00
Proceeds from other investments0.00
Proceeds From Short Term Loans-
Issuances Of Short Term Loans-
Proceeds From Redemption Of Long Term Loans-
Issuances Of Long Term Loans-
Payments For Proceeds From Short Term Investments With Original Maturities Of Three Months Or Less-792.00
Purchases of other investments0.00
Noncontrolling interest0.00
Proceeds from Investments0.00
Proceeds from Sale, Maturity and Collection of Long-term Investments172.00
Purchases of non-current assets0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Proceeds from Sale of Equity Method Investments0.00
Sale of businesses0.00
Proceeds from sale of assets0.00
Notes receivable0.00
Payments for (Proceeds from) Other Investing Activities21.00
Other Net2,261.00
Discontinued operations0.00
Net Cash Flow from Investing Activities2,891.00
Financing Activities
Short-term debt Net-63.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-1,250.00
Noncontrolling interest0.00
Issuances / -repurchases of Comm. Stock0.00
Exercise of stock options0.00
Issuances / -repurchases of Pref. Stock0.00
Discontinued Operations0.00
Other financing activities net-311.00
Other net1.00
Repayments Of Short Term Debt Maturing In More Than Three Months Net Of Repayments Of Short Term Debt Maturing In Three Months Or Less-
Exhange Of Long Term Debt For Retirement Of Short Term Debt-
Receipt Of Common Stock For Retirement Of Short Term Debt-
Transfer Of Certain Product Rights To Equity Method Investment-
Noncash Or Part Noncash Acquisition Debt Assumed-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents1,197.00
Noncashor Part Noncash Divestiture Amount of Consideration Received Common Stock-
Noncashor Part Noncash Divestiture Amount of Consideration Received Note Receivable-
Dividends paid to minority interests0.00
Dividends paid-4,896.00
Net Cash Flow from Financing Activities-6,519.00
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow2,481.00
Total Cash Flow-164.00
4 historic quarters locked

Sign in to unlock the full Pfizer Inc cash flow history.

Sign In Create Free Account

About Pfizer Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260628)
  • Filed with the SEC: August 4, 2026
  • Source: pfe-20260628.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000078003-26-000095

Figures are derived from filed reports and may be restated. Historical data is subject to revision.